ClinicalTrials.gg
Active, not recruitingNCT06150820Updated Nov 9, 2026

A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease

An interventional study of No Intervention in Pompe Disease (Late-onset), sponsored by Astellas Gene Therapies. Active, not recruiting at 53 sites in 11 countries. Open to participants aged 16 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Astellas Gene Therapies (part of Astellas Pharma Inc) · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
119
Allocation
Not applicable
Ages
16 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 93 studies in Glycogen Storage Disease Type II with a site in United States — 11 open to participants now, 20 under way, 3 of them phase 3. Glycogen Storage Disease Type II · United States.

Enrollment
2nd of 60
119 · median 18
Started
2024
with 2 others
No phase
10 of 93
none open now
Primary completion
2027-06
later than 5 of 19 live
Registered
88th of 93
by date
Lead sponsor
2 of 93
Astellas Gene Therapies

Among the 93 studies in Glycogen Storage Disease Type II with a site in United States, this one is the 2nd largest by enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 with no phase, reaches primary completion later than 5 of the 19 other live ones, and was the 88th registered.

Glycogen Storage Disease Type II

162 studies on the registry are indexed under Glycogen Storage Disease Type II; 34 are open to participants now.

Browse Glycogen Storage Disease Type II studies →

Open to participants now

11 of the 93 studies in Glycogen Storage Disease Type II with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Glycogen Storage Disease Type II studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 15 take children under 18; none take healthy volunteers.

This study: 16 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Glycogen Storage Disease Type II with a site in United States, or all of them as a file.
02

Study summary

Pompe disease is a genetic condition which causes muscle weakness over time. People with Pompe disease have a faulty gene that makes an enzyme called acid alpha-glucosidase (or GAA). This enzyme breaks down a type of sugar called glycogen. Without this enzyme, there is a build-up of glycogen in the cells of the body. This causes muscle weakness and other symptoms. Pompe disease can happen at any age, but in late-onset Pompe disease, symptoms generally start from 12 months old onwards.

The standard treatment for people with Pompe disease is to receive regular infusions of the GAA enzyme. This is known as enzyme replacement therapy. However, people can build up antibodies against the GAA enzyme over time.

Gene therapy is used to treat conditions caused by a faulty gene. It works by replacing the faulty gene with a working gene inside the cells of the body. The working gene is delivered into the cells using certain viruses as carriers (vectors). Viruses are often used as carriers as they can easily get inside cells. The genetic material of the original virus is replaced with the working gene, so only the working gene gets inside the cells. A common virus used as a carrier in gene therapy is the adeno-associated virus (or AAV). This is like an adenovirus, which causes the common cold.

The original type of AAV does not cause any harm to humans. However, people that have previously been infected with the original type of AAV may have built up antibodies against AAV. These antibodies may stop the AAV carrier with the working gene getting inside the cells.

Researchers want to learn more about antibody levels against AAV and the GAA enzyme in people with late-onset Pompe disease. They also want to learn about other substances in the blood that provide more information about late-onset Pompe disease. These are known as biomarkers.

In this study, older teenagers and adults with late-onset Pompe disease will take part. They will not have had gene therapy using AAV. There will be 2 groups - those who have never had enzyme replacement therapy, and those who have had enzyme replacement therapy for 6 months or more. No study treatment will be given during the study, but blood and urine samples will be taken for testing.

The main aims of the study are to check antibody levels against AAV8 (a type of AAV) in people with late-onset Pompe disease who had not received any treatment using AAV, to check antibody levels against the GAA enzyme in people previously treated with GAA as part of enzyme replacement therapy, to check levels of biomarkers for Pompe disease, and to check for medical problems.

In the study, people will visit the study clinic several times. Some visits may be in the person's home. The first visit is to check if they can take part. Those who can take part will have a medical examination, and have their vital signs checked. Vital signs include blood pressure, heart rate, breathing rate and temperature. Blood samples will be taken to check antibody levels against the GAA enzyme and against AAV8. Blood and urine samples will also be taken to check for biomarkers for Pompe disease. Blood and urine samples will be taken about every 4 months for up to 2 years.

Read the detailed description

No investigational drug will be administered to participants in this study. Blood and urine will be collected as part of the study. The duration of the study is approximately 2 years, participants may withdraw at any time.

03

Conditions studied

  • Pompe Disease (Late-onset)

Keywords

  • Pompe Disease (Late-onset)
  • Antibodies to AAV8
  • Biomarkers
04

Who can participate

Ages eligible
16 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a documented clinical diagnosis of LOPD.
  • Participant is enzyme replacement therapy ERT-naïve (ERT-N) or if the participant is currently taking an approved ERT treatment or is participating in an ERT-interventional study, the ERT must have been received for at least 6 months or more (ERT-experienced [ERT-E]).
  • Participant is willing and able to comply with study visits and procedures.
  • Participant agrees to not start participating in any other clinical study involving an study treatment, including ERT, while participating in this study.

Exclusion criteria

Exclusion Criteria:

  • Participant previously received an AAV-related product (any serotype).
  • Participant is currently participating in a Pompe-related interventional study (other than ERT-interventional studies) or has received gene or cell therapy.
  • Participant requires any invasive or noninvasive ventilation support while awake and upright (non-invasive support while sleeping with either continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) is acceptable for eligibility).
  • Participant is unable to ambulate (assistive devices [e.g., cane or walker] are acceptable for eligibility).
  • Participants who have received any ERT for less than 6 months as of the Baseline visit are not eligible.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Other
    Participants with Late-Onset Pompe Disease

    Adolescent or adult participants with LOPD.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    No investigational drug will be administered to participants in this study.

06

What researchers measure

Primary outcomes

  1. Occurrence of total antibodies to AAV8

    Antibodies to AAV8 will be recorded from serum blood samples collected.

    Time frame: Up to 2 years

  2. Occurrence of neutralizing antibodies to AAV8

    Antibodies to AAV8 will be recorded from serum blood samples collected.

    Time frame: Up to 2 years

Secondary outcomes

  1. Seroconversion of antibodies to AAV8 over time

    Seroconversion of antibodies to AAV8 will be recorded from serum blood samples collected.

    Time frame: Up to 2 years

  2. Creatine kinase [CK] levels

    CK levels will be recorded from blood plasma samples collected.

    Time frame: Up to 2 years

  3. Urine glucose tetrasaccharide [Glc4]/hexose tetrasaccharide [Hex4] over time

    Glc4/Hex4 will be recorded from urine samples collected.

    Time frame: Up to 2 years

  4. Occurrence of anti-GAA antibodies in participants on ERT

    Anti-GAA antibodies will be recorded from serum blood samples collected.

    Time frame: Up to 2 years

07

Study locations

53 sites
  • Emory Clinic
    Atlanta, Georgia 30322, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Children's Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • University of Cincinnati
    Cincinnati, Ohio 45221, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • University of UTAH - PPDS
    Salt Lake City, Utah 84132, United States
  • Lysosomal and Rare Diseases Research and Treatment Center, Inc.
    Fairfax, Virginia 22030, United States
  • AU61003
    Adelaide, Australia
  • AU61001
    Herston, Australia
  • BR55003
    Flamengo, Brazil
  • BR55002
    Porto Alegre, Brazil
  • BR55001
    São Paulo, Brazil
  • CN15003
    Edmonton, Canada
  • CA15001
    Montreal, Canada
  • FR33006
    Angers, France
  • FR33009
    Garches, France
  • FR33005
    Lille, France
  • FR33007
    Limoges, France
  • FR33002
    Marseille, France
  • FR33003
    Nantes, France
  • FR33004
    Nice, France
  • FR33001
    Strasbourg, France
  • DT49005
    Bonn, Germany
  • DT49004
    Essen, Germany
  • DT49003
    Höchheim, Germany
  • DT49006
    Münster, Germany
  • IT39002
    Florence, Italy
  • IT39005
    Gussago, Italy
  • IT39012
    Messina, Italy
  • IT39009
    Milan, Italy
  • IT39011
    Milan, Italy
  • IT39008
    Pavia, Italy
  • IT39006
    Pisa, Italy
  • IT39004
    Roma, Italy
  • IT39003
    Udine, Italy
  • National Center of Neurology and Psychiatry
    Kodaira-Shi, Japan
  • Tokyo Women's Medical University Hospital
    Shinjuku-Ku, Japan
  • ES34003
    Albacete, Spain
  • ES34004
    Barcelona, Spain
  • ES34009
    Donostia / San Sebastian, Spain
  • ES34007
    L'Hospitalet de Llobregat, Spain
  • ES34001
    Madrid, Spain
  • ES34005
    Madrid, Spain
  • ES34002
    Valencia, Spain
  • TW88601
    Taipei, Taiwan
  • TW88602
    Taipei, Taiwan
  • TW88603
    Taoyuan City, Taiwan
  • UK44003
    Cambridge, United Kingdom
  • UK44001
    Newcastle upon Tyne, United Kingdom
  • UK44004
    Salford, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jun 2027, 40 months after the start.

Of 16 interventional studies with no phase under Glycogen Storage Disease Type II, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2023
First posted
Nov 29, 2023
StartActual
Feb 1, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 8, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06150820
Responsible party
Sponsor
First posted
Nov 29, 2023
Start date
Feb 1, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Medical Director
study director · Astellas Gene Therapies

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion